Context Therapeutics discontinues ONA-XR, prioritizes CTIM-76; 2022 net loss $14.8M

Context Therapeutics Inc.

Discontinued ONA-XR due to elevated LFTs in 3 patients and competitive landscape; exploring strategic options.
Focusing on CTIM-76 (CLDN6 x CD3 bispecific) for solid tumors; IND expected Q1 2024.
Cash $35.5M at Dec 31, 2022, down from $49.7M; cash runway extended into late 2024.
2022 net loss $14.8M vs $10.5M in 2021; R&D $7.1M, G&A $7.8M.
CTIM-76 preclinical data at AACR April 17, 2023; investor R&D webinar same day.

item 2.02 item 2.05 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Context Therapeutics Inc. reported the year ended December 31, 2022 results: net income $14.8 million.

Period: the year ended December 31, 2022
Net income: $14.8 million
Result: reported results

Exact text from the filing

Context reported a net loss of $14.8 million for 2022, as compared to $10.5 million for the same period in 2021.

View on SEC.gov

Browse all earnings releases →

Context Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001842952-23-000040

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.